Revenues, Recognition and Allowances (Details Textual) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018 USD ($) transaction_type segment	Jun. 30, 2017 USD ($)	Jun. 30, 2018 USD ($) transaction_type	Jun. 30, 2018 USD ($) transaction_type	Jun. 30, 2018 USD ($) drug transaction_type	Jun. 30, 2018 USD ($) transaction_type product	Jun. 30, 2018 USD ($) transaction_type segment	Jun. 30, 2018 USD ($) transaction_type	Jun. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)
Disaggregation of Revenue [Line Items]
Types of transactions | transaction_type	3		3	3	3	3	3	3
Segments | segment	1						1
Company product sales, net	$ 15,179	$ 15,888						$ 28,415	$ 32,324
Accounts payable and accrued liabilities	0	5,500	$ 0	$ 0	$ 0	$ 0	$ 0	0	5,500
Increase (decrease) to medicaid reserve								(800)
Accounts receivable, terms of customer credit			100 days
Percentage of net sales for royalty				40.00%
Royalties	578	400	$ 578	$ 578	$ 578	$ 578	578	578	400	$ 856
Royalty expense	700	400						1,500	900
United States
Disaggregation of Revenue [Line Items]
Products which the company pays royalties					4	4
Products manufactured, marketed and distributed | drug					30
IGI Product
Disaggregation of Revenue [Line Items]
Company product sales, net	15,200	15,900						28,400	32,300
Net Of SRA Balance
Disaggregation of Revenue [Line Items]
Accounts receivable	$ 19,300	$ 30,900	$ 19,300	$ 19,300	$ 19,300	$ 19,300	$ 19,300	$ 19,300	$ 30,900